Group 1 - Barclays has cut the price target for Blackstone Inc. (BX) from $164 to $126 while maintaining an Equal Weight rating, citing early uncertainty regarding the impact of AI on portfolio companies and lowering earnings estimates for business development companies due to reduced flow assumptions [1] - Blackstone Life Sciences (BXLS) announced a funding agreement to advance the clinical development of bleximenib, an investigational oral menin inhibitor for acute myeloid leukemia (AML), which is noted as a challenging ailment with the lowest survival rates among leukemia types [2] - The co-funding agreement between Blackstone Inc. and Johnson & Johnson for the clinical trials of bleximenib marks a significant collaboration, indicating a strategic partnership in the healthcare sector [3] Group 2 - The investment landscape is shifting, with certain AI stocks being perceived as having greater upside potential and lower downside risk compared to Blackstone, suggesting a competitive environment for investment opportunities [4]

Core Viewpoint - Goldman Sachs has reduced its price target for Blackstone Inc. to $158 from $166 while maintaining a Neutral rating, forecasting a 12% compound annual growth rate in core management fees from 2025 to 2028 [1] - Citizens maintained a Market Outperform rating for Blackstone, highlighting a compelling positioning going into 2026 after strong fourth-quarter 2025 earnings [2] Group 1: Financial Performance and Projections - Goldman Sachs projects a 12% CAGR in Blackstone's core management fees and a 16% CAGR in fee-related earnings (FRE) from 2025 to 2028 [1] - Blackstone is trading at approximately 20 times the 2027 P/E ratio net of equity-based compensation, indicating a more digestible valuation amid a cyclical boost to PRE estimates in 2027 [2] - Blackstone delivered strong fourth-quarter 2025 earnings, which included a meaningful headline earnings beat [2] Group 2: Company Overview - Blackstone Inc. provides investment and fund management services, with operations divided into segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions [2]